Overview
Starting July 1, 2026, Medicare will launch a short-term pilot called the Medicare GLP‑1 Bridge that lets some beneficiaries obtain certain GLP‑1 prescription medications for weight loss for a flat $50 monthly copay. The Bridge runs through Dec. 31, 2027, and is meant to provide temporary access while policymakers consider a longer-term approach in 2028.
Which drugs are included
Covered medications are those FDA-approved for weight loss and include both pill and injectable formulations such as Wegovy (pill and injectable), the KwikPen formulation of Zepbound, and the Foundayo pill. These medicines can be effective but are often costly; typical cash prices (after some discounts) currently range roughly from $149 to $699 per month. Polling from KFF found about half of GLP‑1 users struggled to afford these drugs, with about a quarter saying they were very difficult to afford.
Who is eligible
– You must be enrolled in a Medicare Part D drug plan to participate.
– Eligibility is mainly clinical: people with BMI 35 or higher qualify automatically. Those with BMI 27 or higher may qualify if they have a qualifying health condition such as heart disease or prediabetes. (For context, CDC data show roughly 40% of U.S. adults have obesity defined as BMI 30 or higher.)
How the Bridge works
– The Bridge does not run through your Part D plan’s usual pharmacy processing. Prescriptions require prior authorization through a centralized system operated by Humana under contract with CMS, using an existing Medicare drug platform.
– Prescribers do not need to be enrolled Medicare providers to submit prior authorization requests through this system. Once approved, the beneficiary pays a $50 copay at the pharmacy.
– The $50 copay is fixed and does not increase at higher doses, which many patients need to maintain weight loss.
Potential benefits
– A predictable $50 monthly copay could make these drugs accessible to people who previously could not afford them, and for many that will be substantially less than retail or some direct-to-consumer discounted prices.
– A uniform copay regardless of dose matters because higher doses are commonly required for sustained weight loss.
Limitations and downsides
– The $50 copay paid under the Bridge does not count toward a Part D plan deductible or toward the $2,100 annual out‑of‑pocket cap for prescription drugs.
– The Bridge is temporary and ends Dec. 31, 2027. Evidence shows many people regain weight after stopping GLP‑1 drugs, so temporary access raises questions about long-term outcomes and costs.
– Medicare’s low-income subsidy (Extra Help) cannot be applied to drugs obtained through the Bridge; beneficiaries used to $5 or $10 copays may still find $50 unaffordable.
– If you already take a GLP‑1 for another covered indication—such as type 2 diabetes, cardiovascular risk reduction, or sleep apnea—you will continue to get that drug through your regular Part D plan and pay that plan’s cost, which could be higher than the Bridge’s $50 copay. The same medicine might cost different amounts depending on the indication.
Continuity for people already on therapy
If you started a GLP‑1 for weight loss before the Bridge begins, you may still qualify. Your prescriber must attest that you met the clinical eligibility criteria when treatment began (for example, that your BMI met the threshold at therapy initiation), even if your current BMI is lower.
Why the program is temporary and what comes next
The administration originally proposed a two-step approach: a short Bridge followed by a longer-term program that would shift drug costs onto insurers. A study estimated that the long-term model could cost insurers billions in the first year. Not enough insurers agreed to the plan by the deadline, so CMS extended the Bridge to 18 months to collect more data and give insurers time to negotiate. CMS has not released public projections for enrollment or expenses; analysts say costs could range into the billions depending on uptake. The extension is intended to supply more information to insurers and policymakers before any permanent change.
Other considerations
– People who stop GLP‑1 therapy commonly regain weight, which complicates assessments of the program’s long-term clinical and budgetary impact.
– The program’s centralized prior authorization process is an unusual arrangement for a Medicare drug benefit and departs from the typical Part D plan-based workflow.
If you’re interested
If you’re on Medicare and considering a GLP‑1 for weight loss: confirm you have Part D coverage, discuss clinical eligibility and the prior authorization process with your prescriber, and weigh whether a $50 monthly copay and the Bridge’s temporary nature make sense for your situation.